Quarterly Report · 10-Q

Scilex Holding Company

SCLXNASDAQEQUITYCurrent

Quarterly Report

Filed May 20, 2026Accepted May 20, 2026, 5:22 PM EDTCIK 1820190Accession 0001193125-26-232857

Company context

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a

Current securities

SCLXNASDAQ · EQUITY · Current SCLXWNASDAQ · WARRANT · Current

Historical securities (3)

VCKANASDAQ · EQUITY · Historical · closed Nov 10, 2022 VCKAUNASDAQ · UNIT · Historical · closed Nov 10, 2022 VCKAWNASDAQ · WARRANT · Historical · closed Nov 10, 2022

Recent company filings

Registered securities in this filing

Scilex Holding Company · 10-Q · Filed 2026-05-20

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: SCLX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_3f542961-cae9-4c3f-8cac-c102f0f0af66

Dimensions: Not supplied

Accession 000119312526232857 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.